Using machine learning for mortality prediction and risk stratification in atezolizumab‐treated cancer patients: Integrative analysis of eight clinical trials

BACKGROUND: Few models exist to predict mortality in cancer patients receiving immunotherapy. Our aim was to build a machine learning‐based risk stratification model for predicting mortality in atezolizumab‐treated cancer patients. METHODS: Data from 2538 patients in eight atezolizumab‐treated cancer clinical trials across three cancer types (non‐small‐cell lung cancer, bladder transitional cell carcinoma, and renal cell carcinoma) were included. The whole cohort was randomly split into development and validation cohorts in a 7:3 ratio. Machine‐learning algorithms (extreme gradient boosting, random forest, logistic regression with lasso regularization, support vector machine, and K‐nearest neighbor) were applied to develop prediction models. Model performance was mainly assessed by area under the receiver operating characteristic curve (AUC) value, calibration plot, and decision curve analysis. The probability of death risk was then stratified. RESULTS: One thousand and three hundred and seventy‐nine (54.33%) patients died. The random forest (RF) model was overall the best in terms of predictive performance, with the AUC of 0.844 (95% confidence interval [CI]: 0.826–0.862) in the development cohort and 0.786 (95% CI: 0.754–0.818) in the validation cohort for predicting mortality. Twelve baseline variables contributing to mortality prediction in the RF model were C‐reactive protein, PD‐L1 level, cancer type, prior liver metastasis, derived neutrophil‐to‐lymphocyte ratio, alkaline phosphatase, albumin, hemoglobin, white blood cell count, number of metastatic sites, pulse rate, and Eastern Cooperative Oncology Group (ECOG) performance status. A total of 1782 (70.2%) patients were separated into the high‐risk and 756 (29.8%) low‐risk groups. Patients in the high‐risk group were significantly more likely to die, experience disease progression, discontinue study, and discontinue treatment than patients in the low‐risk group (all p values < 0.001). Risk groups were not associated with immune‐related adverse events and grades 3–5 treatment‐related adverse events (all p values > 0.05). CONCLUSION: RF model has good performance in mortality prediction and risk stratification for cancer patients receiving atezolizumab monotherapy.